Citigroup Boosts Stake in Akebia Therapeutics by Over 1,300%

The financial firm now owns nearly 2 million shares in the biopharmaceutical company.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Citigroup Inc. significantly increased its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) by 1,324.7% in the third quarter, according to a recent SEC filing. The firm now owns 1,916,692 shares of the biopharmaceutical company's stock, worth approximately $5.23 million.

Why it matters

This large investment by a major financial institution like Citigroup suggests they see significant potential in Akebia Therapeutics and its biopharmaceutical pipeline. Akebia is focused on developing therapies for patients with kidney disease, an area of growing importance as the population ages.

The details

Citigroup purchased an additional 1,782,162 shares of Akebia Therapeutics during the third quarter, bringing its total ownership to about 0.72% of the company. Akebia is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts that is focused on developing treatments for kidney disease.

  • Citigroup increased its stake in Akebia Therapeutics during the third quarter of 2025.

The players

Citigroup Inc.

A major American multinational investment bank and financial services corporation.

Akebia Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing therapies for patients with kidney disease.

Got photos? Submit your photos here. ›

The takeaway

Citigroup's substantial investment in Akebia Therapeutics suggests the financial firm sees strong potential in the biopharmaceutical company's pipeline of kidney disease treatments, underscoring the growing importance of this therapeutic area.